Study Phase 3

The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years

Trial Information

Generic NameRisperidoneProduct NameRISPERDAL CONSTA®Therapeutic AreaBehaviors and Mental DisordersEnrollment110% Female25%% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberCR006007 (RIS-CAN-19)Data PartnerJohnson & JohnsonCondition StudiedAttention Deficit and Disruptive Behavior Disorders, Attention Deficit Hyperactivity Disorder, Conduct DisorderMean/Median Age (Years)9

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.